Indian Journal of Psychiatry (ISSN: 0019-5545, E-ISSN: 1998-3794) is a premier, peer-reviewed academic journal published by WOLTERS KLUWER MEDKNOW PUBLICATIONS. As a leading publication in the field of psychiatry and mental health since its establishment in 1970, the journal has significantly contributed to the advancement of psychiatric research and clinical practice in India and globally. With an impact factor reflecting its robust academic reputation, the journal is categorized under the Q3 quartile in its field for 2023 and ranks #228 out of 567 in the Scopus rankings. This Open Access journal has been providing cutting-edge research insights since 2007, ensuring that access to vital findings and innovative methodologies is available to a wide readership without restrictions. The Indian Journal of Psychiatry is dedicated to the dissemination of quality research, clinical studies, and reviews, aiming to enhance understanding and treatment of mental health disorders. It serves as an essential resource for researchers, practitioners, and students striving to improve mental health outcomes in diverse populations.

Psychiatry and Clinical Psychopharmacology, an open-access journal published by AVES since 2017, is dedicated to advancing the fields of psychiatric medicine and psychopharmacology. With an ISSN of 2475-0573 and an E-ISSN of 2475-0581, this journal aims to provide a platform for disseminating innovative research and clinical findings relevant to mental health professionals and researchers. Although it currently holds a Q3 ranking in Pharmacology (medical) and a Q4 ranking in Psychiatry and Mental Health according to the 2023 category quartiles, the journal has established itself as a significant contributor to evolving discussions in these critical fields. Based in the United Kingdom, the journal encompasses diverse topics, ranging from pharmacological treatments to novel therapeutic approaches in psychiatry, thereby appealing to a broad audience of clinicians, scientists, and students. The open-access model ensures that all research is readily available, fostering an environment of collaboration and knowledge-sharing as the journal converges until 2024 to encompass the latest advancements in both pharmacology and clinical psychopharmacology.

Biological Psychiatry is a premier journal dedicated to advancing the understanding of the biological underpinnings of psychiatric disorders. Published by Elsevier Science Inc, this esteemed journal is recognized globally for its rigorous peer-reviewed research and contributes significantly to the field of biological psychiatry. With an impressive impact factor that places it in Q1 of its category and ranks 3rd out of 51 in Neuroscience Biological Psychiatry, it reflects the journal's strength in disseminating high-quality findings that push the boundaries of knowledge. Since its inception in 1969, the journal has undergone continuous evolution, aiming to integrate biological and clinical perspectives to optimize the understanding of mental health conditions. Although it does not offer open access, Biological Psychiatry serves as a critical resource for researchers, practitioners, and students, offering insights that influence both theoretical frameworks and practical applications in the realm of psychiatric science.

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, a premier academic journal published by TAYLOR & FRANCIS LTD, stands at the forefront of interdisciplinary research in the fields of Biological Psychiatry, Psychiatry, and Mental Health. Based in the United Kingdom, this esteemed journal (ISSN: 1562-2975; E-ISSN: 1814-1412) has become increasingly influential since its inception in 2000, with a remarkable impact factor that reflects its high-quality research contributions. The journal is consistently ranked in the Q1 and Q2 categories across various relevant indices, demonstrating its reputation for excellence within the academic community. With Scopus rankings placing it in the top 20th percentile for Psychiatry and Mental Health, the WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY serves as a vital resource for researchers, professionals, and students seeking to further their understanding of the intricate relationship between biological processes and psychiatric phenomena. Despite being a traditional access journal, it possesses a robust scope that encompasses groundbreaking studies, reviews, and advancements in the understanding of mental health disorders, underlining its importance as a key reference in the advancement of psychiatric science and therapeutic practices.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a leading peer-reviewed journal that serves the interdisciplinary field of neuropsychopharmacology and biological psychiatry. With an impressive impact factor in the first quartile of both Biological Psychiatry and Pharmacology categories, this journal provides a critical platform for the dissemination of cutting-edge research and innovative therapeutic approaches. Covering a broad range of topics from the molecular mechanisms underlying psychiatric disorders to advanced pharmacological interventions, it aims to foster scientific dialogue among researchers, clinicians, and students alike. The journal has been at the forefront of scientific inquiry since its inception in 1982 and continues to evolve, adapting to the ever-changing landscape of neuroscience and mental health research. With its focus on high-quality articles and a commitment to advancing the understanding of neuropsychopharmacology, this journal is essential for anyone interested in the complexities of brain function and mental health.

Neuropsychopharmacology Reports is a leading open-access journal published by WILEY, dedicated to advancing the fields of clinical psychology, pharmacology, psychiatry, and mental health. Established in 2018, the journal aims to disseminate high-quality research findings, critical reviews, and innovative methodologies that elucidate the complexities of neuropsychopharmacology in enhancing mental health outcomes. With an impressive impact indicated by its Q2 rankings in several categories including Clinical Psychology and Pharmacology (medical) as of 2023, Neuropsychopharmacology Reports stands out as a vital resource for researchers, professionals, and students keen on exploring the interplay between pharmacological interventions and psychological well-being. The journal’s open-access nature ensures that critical advancements in this rapidly evolving field are readily available to a global audience, fostering collaboration and discourse among scholars and practitioners alike. Building on its indexed status with Scopus, the journal is positioned as a noteworthy contributor to ongoing discussions and developments in psychiatry and medical pharmacology.

The Brazilian Journal of Psychiatry is a prominent peer-reviewed journal dedicated to advancing the field of psychiatry and mental health, published by the Associação Brasileira de Psiquiatria. With an impressive Q2 ranking in the Psychiatry and Mental Health category for 2023 and a Scopus rank of #130 out of 567, this journal serves as a vital resource for researchers, clinicians, and students alike. Since its transition to Open Access in 1999, it has aimed to disseminate high-quality research, innovative practices, and critical insights relevant to mental health in Brazil and beyond. The journal's focus spans various topics in psychiatry, aiming to bridge the gap between research and clinical application, making it essential reading for professionals and academicians committed to improving mental health outcomes. With a commitment to fostering scholarly discourse, the Brazilian Journal of Psychiatry not only enriches the academic landscape but also enhances the practice of psychiatry through its widespread accessibility and dedication to excellence in research.

INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE is a distinguished publication dedicated to advancing the understanding of psychiatric practice and mental health issues within a medical framework. Published by SAGE PUBLICATIONS INC, this journal has been a trusted source in the field since its inception, with its archives dating back to 1973. It offers a comprehensive exploration of psychiatric research, clinical studies, and theoretical advancements that seek to bridge the gap between psychiatry and general medicine. With an impact factor reflective of its quality and relevance, categorized in the Q3 quartile in Psychiatry and Mental Health, this journal stands as a vital resource for researchers, clinicians, and students alike. Although operating on a traditional subscription model, the extensive knowledge shared within its pages contributes significantly to ongoing discussions in psychiatric and mental health education and practice. As the field continually evolves, the INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE remains committed to fostering innovative and impactful scholarship that resonates with professionals navigating the complexities of mental health in clinical contexts.

Schizophrenia Research and Treatment, an esteemed journal published by HINDAWI LTD, serves as a pivotal open-access platform for innovative research in the fields of Neurology and Psychiatry. With an ISSN of 2090-2085 and E-ISSN of 2090-2093, this journal has established itself as a significant resource for scholars and practitioners since its inception in 2011, consistently contributing to the understanding and treatment of schizophrenia and related mental health issues. Based in Egypt and reaching a global audience, Schizophrenia Research and Treatment is classified in the 2023 Q2 category for both Neurology (Clinical) and Psychiatry and Mental Health, reflecting its importance and relevance in these disciplines. Notably, the journal ranks in the 61st percentile for Psychiatry and Mental Health and the 58th percentile for Clinical Neurology, indicating its solid reputation among peers. By disseminating critical findings and fostering dialogue among researchers, professionals, and students, this journal plays a crucial role in advancing the treatment and management of schizophrenia, ultimately benefiting patients and healthcare systems worldwide.

Biological Psychiatry-Cognitive Neuroscience and Neuroimaging is a leading interdisciplinary journal published by Elsevier, focusing on the convergence of biological psychiatry, cognitive neuroscience, and advanced neuroimaging techniques. With its prestigious Q1 rankings across essential categories such as Biological Psychiatry, Cognitive Neuroscience, and Neurology (clinical), this journal is at the forefront of research that examines the complexities of mental health through innovative methodologies. Covering a broad spectrum of topics from neurobiological mechanisms to clinical applications, it aims to provide a platform for scholars and practitioners to exchange insights on mental disorders and their neurobiological underpinnings. The impact factor and Scopus rankings further underscore its importance, with rankings highlighting its position in the top percentiles of related disciplines. By fostering an open exchange of ideas and promoting cutting-edge research, this journal is an essential resource for researchers, professionals, and students dedicated to advancements in the understanding and treatment of psychiatric and neurological conditions.